Polaryx Therapeutics Debuts on Nasdaq via Direct Listing, Eyes Phase 2 Trial Launch — Polaryx Therapeutics, Inc.

Event summary

Polaryx Therapeutics begins trading on Nasdaq under ticker 'PLYX' via direct listing on February 2, 2026.
Company plans to initiate Phase 2 SOTERIA trial for lead drug candidate PLX-200 in H1 2026.
SOTERIA trial will assess PLX-200 across four lysosomal storage disorders (CLN2, CLN3, Krabbe, Sandhoff).
Trial includes natural history data comparisons for CLN2 and CLN3 cohorts.
Maxim Group LLC served as exclusive financial advisor for the direct listing.

The big picture

Polaryx's Nasdaq debut comes as biotech companies increasingly turn to direct listings to access public markets without traditional IPO underwriting fees. The timing of the listing aligns with the planned launch of the SOTERIA trial, positioning Polaryx to potentially accelerate development of its lead candidate PLX-200 for multiple rare lysosomal storage disorders. The company's approach of integrating small molecule therapies with gene therapy reflects broader industry trends toward combination treatments for complex genetic diseases.

What we're watching

Trial Execution: Whether the flexible, resource-efficient design of the SOTERIA trial will successfully validate PLX-200's preclinical science across multiple indications.
Regulatory Pathway: The pace at which Polaryx may seek conditional marketing authorization based on SOTERIA trial results.
Market Performance: How Polaryx's direct listing will be received by investors given the company's clinical-stage status and the upcoming catalyst of the SOTERIA trial.